PF-Atlas › Mechanisms › Anti-CTGF/CCN2

Anti-CTGF/CCN2 in IPF

Mechanism of action · idiopathic pulmonary fibrosis

Overview

Anti-CTGF/CCN2 is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 1 clinical trial acting through this mechanism.

Drugs targeting Anti-CTGF/CCN2

Pamrevlumab

Clinical trials

Pamrevlumab — ZEPHYRUS-2
Medical disclaimer. This is a research summary, not medical advice.